Drug intelligence / Profile preview

TAK-671

Development stage: Discontinued
Lead developer: Takeda
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

TAK-671 is a recombinant human monoclonal antibody developed by Takeda for the treatment of COVID-19. It was designed to target the spike protein of the SARS-CoV-2 virus, specifically neutralizing the virus to prevent its entry into host cells. The drug was investigated in a Phase 1b clinical trial (NCT04570319) targeting hospitalized adults with severe COVID-19. In 2021, Takeda terminated the development of TAK-671, citing the rapidly evolving treatment landscape and the availability of alternative therapeutic options.

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on TAK-671.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TAK-671.

Explore the full profile